Contemporary Pediatrics’ top 3 FDA approvals of 2024
From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.
What's going on with polio, monkeypox, and COVID-19
The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?
Early HPV vaccination boosts completion rates
Early HPV vaccination at age 9 boosts completion rates, reduces disparities, and enhances cancer prevention effort, according to a recent study from Nemours Children's Health.
What Omicron could mean for the pandemic
Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.
A preview of the November/December issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year.
Zelicapavir demonstrates antiviral effect in phase 2 RSV study
Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.
